Meeting
2019 ASCO Annual Meeting
RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).
Authors
Anica Högner
Charité–University Medicine Berlin, Department of Haematology, Oncology and Tumorimmunology, Berlin, Germany
Anica Högner , Kirstin Breithaupt , Alexander Stein , Axel Hinke , Mario Lorenz , Salah-Eddin Al-Batran , Peter C. Thuss-Patience
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
AIO-STO-0218
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4148)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4148
Abstract #
TPS4148
Poster Bd #
249b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).
First Author: Peter C. Thuss-Patience
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price
Poster
2022 ASCO Annual Meeting
Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
First Author: Peter C. Thuss-Patience
Poster
2021 ASCO Annual Meeting
Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).
First Author: Rika Saito